ASCO 2022: Focus on GVHD

DocWire News EditorsASCO 2022 | April 3, 2023

In a meta-analysis presented at the 2022 American Society of Clinical Oncology Annual Meeting, researchers evaluated ...

DocWire News EditorsASCO 2022 | October 16, 2023

According to research presented at the 2022 American Society of Clinical Oncology Annual Meeting, graft-versus-host ...

DocWire News EditorsASCO 2022 | August 25, 2023

Hispanic patients had a significantly lower cumulative incidence of chronic graft-versus-host disease (GVHD) than ...

$No GVHD Reported in First-in-Human Trial of ADI-001 CAR-T for Relapsed/Refractory Advanced B-Cell Lymphoma$

DocWire News EditorsASCO 2022 | October 16, 2023

The first-in-human, phase I clinical trial of ADI-001, an allogeneic gamma delta chimeric antigen receptor (CAR) T-cell ...

$Literature Review Assesses Use of Ruxolitinib in Chronic Steroid-Refractory GVHD$

DocWire News EditorsASCO 2022 | September 26, 2023

A study presented at the 2022 American Society of Clinical Oncology Annual Meeting reported on results of a literature ...

DocWire News EditorsASCO 2022 | October 16, 2023

Patients who received an allogeneic hematopoietic stem cell transplant (HSCT) from matched related donors (MRD) or ...

DocWire News EditorsASCO 2022 | September 21, 2023

A study presented at the 2022 American Society of Clinical Oncology Annual Meeting found that an autologous CD7 chimeric ...

DocWire News EditorsASCO 2022 | October 16, 2023

A retrospective study found that partially mismatched blood or marrow transplantation with post-transplantation ...